myeloablative in all cases. Overall survival, leukemia free survival (LFS) and relapse incidence (RI) at 3 years were 57±4%, 49±4% and 45±3%, respectively. Only 4 patients (1.9%) had VOD (moderate-2, severe-2) at median day 16 range (10-47). One of the patients died from VOD. Non relapse mortality at 3 years was low 6±1%. In multivariate analysis the only prognostic factor that was found to be significant for OS, LFS, RI and NRM was age >50 vs <50 years with p-value of <0.001, <0.001, <0.006 and <0.001, respectively (47±5%, 38±5%, 52±5%, 10±3% vs 68±5%, 76±4%, 32±5% and 0%, respectively).

In summary, these results suggest, that similar to the allogeneic setting, VOD is a very uncommon event after AutoSCT using iv Bu in the conditioning regimen translating into a low NRM incidence.

O345 Intravenous busulfan plus cyclophosphamide (Cyt) versus TBI plus cyclophosphamide for allogeneic stem cell transplantation from mismatched unrelated donors. In adult patients with AML in first relapse: a survey from the ALWP of EBMT

A. Nagler (1), M. Labopin (2), A. Shimoni (1), J. Finke (3), D. Beelen (4), L. Violin (5), J. Passweg (6), R. Schwerdtfeger (7), H. Kolth (8), A. Anagnostopoulos (9), V. Rocha (10), F. Ciceni (11), M. Mothy (12)

(1)Chaim Sheba Medical Center (Tel Hashomer, IL); (2)Hospital Saint-Antoine, and EBMT ALWP Ofﬁce Universite Pierre et Matie Curie (Paris, FR); (3)University Hospital (Freiburg, DE); (4)University Hospital Essen; (5)Helsinki University Central Hospital (Helsinki, FI); (6)University Hospital Basel (Basel, CH); (7)Deutsche Klinik fuer Diagnostik (Wiesbaden, DE); (8)Ludwig-Maximilians-University (Munich, DE); (9)George Papanicolaou Hospital (Thessaloniki, GR); (10)Hopital Saint Louis APHP, EBMT ALWP and University of Paris VII (Paris, FR); (11)San Raffaele Scientiﬁc Institute (Milan, IT); (12)University of Nantes (Nantes, FR)

We compared TBI/Cy to iv Bu/Cy conditioning prior to alloSCT from HLA matched unrelated donors in 169 adult pts with AML in Rel 1. 95 pts were given TBI/Cy and 74 Bu/Cy. Median age was 38 (18-62) and 42 (19-72) years in the TBI/Cy vs Bu/Cy groups, respectively (P=0.005). FAB classification, cytogenetic risk, time from diagnosis to alloSCT, donor gender and CMV serostatus did not differ between the groups. Median year of alloSCT was 2004 vs. 2007, respectively (P<0.001). ATG was serostatus did not differ between the groups. Median year of alloSCT was 2004 vs. 2007, respectively (P<0.001). ATG was


We investigated the impact of occurrence of GVHD on transplantation outcomes in a large cohort of AML pts given allogeneic PBSC after RIC conditioning. Data from 1859 AML pts in first (n=1439) or second (n=420) CR transplanted between 2000 and 2009 following a RIC regimen at EBMT afﬁliated centers were analyzed. Pts were given PBSCC from HLA-identical sibling (MRD, n=1208), or from HLA-matched unrelated donors (MUD, n=651). ATG was given in 269 (22%) MRD and in 267 (41%) MUD recipients, respectively, while 151 (13%) MRD and 165 (25%) MUD recipients received in-vivo T cell depletion with alemtuzumab. The impact of chronic GVHD (cGVHD) on outcome was assessed using time-dependent multivariate Cox models and in a landmark analysis at 18 months after transplant. The 3-y cumulative incidence of cGVHD was 47%. Fifty-three percent of patients with cGVHD had extensive cGVHD, while the remaining 47% had limited cGVHD. In multivariate analyses, occurrence of grade II-IV aGVHD was associated with a lower risk of relapse (HR=0.8, P=0.04), a higher risk of chronic (HR=2.2; P<0.001) and extensive chronic GVHD (HR=2.8; P=0.001), a higher risk of NRM (HR=2.4 P<0.001), a worsened LFS (HR=1.3; P=0.01), and a worsened OS (HR=1.5; P<0.001).

In multivariate time-dependent analyses, occurrence of limited cGVHD was associated with a lower risk of relapse (HR=0.7; P=0.05), comparable NRM (HR=1.4; P=0.16), comparable LFS (HR=0.9; P=0.29) and better OS (HR<0.5; P<0.001), while occurrence of extensive cGVHD was associated with a lower risk of relapse (HR=0.6; P=0.01), higher NRM (HR=3.2; P<0.001), a trend for worsened LFS (HR=1.3; P=0.06) and comparable OS (HR=0.9; P=0.34). In a landmark analysis in patients who were leukemia-free at 16 months after transplantation (n=776), 2-year relapse, NRM, LFS and OS were 16±2%, 2±6%, 82±2% and 89±2%, respectively. In patients without cGVHD before the landmark time-point, versus ≥±1% (P=0.001), ≥±1% (P<0.001), 83±2% (P=0.65) and 86±2% (P=0.38), respectively, in patients with cGVHD before the landmark time-point. In conclusion, in this cohort of AML patients transplanted in remission, occurrence of cGVHD was associated with a lower risk of relapse that translated to better OS in patients with limited cGVHD but not in those with extensive cGVHD who experienced higher long term NRM. These results highlight the role of the GVT effect in RIC allo-SCT, but also the need for improving the prevention of severe cGVHD in pts receiving RIC allo-SCT.

O347 Impact of alemtuzumab versus anti-thymocyte globulin after unrelated allogeneic stem cell transplantation with reduced-intensity conditioning as treatment for AML in CR1: a survey from the Acute Leukaemia Working Party of the EBMT

F. Baron, M. Labopin, G. Mufti, R. Arnold, C. Craddock, K. Bilger, N. Kroger, A. Nagler, M. Mothy on behalf of the acute leukaemia working party

In vivo T cell depletion of the graft with anti-thymocyte globulin (ATG) or with alemtuzumab has been frequently used in the